BMO ASSET MANAGEMENT INC EQUAL WEIGHT US HEALTH CARE HEDGED TO CA (ZUH)
- 77.300
- -0.260-0.34%
BMO ASSET MANAGEMENT INC EQUAL WEIGHT US HEALTH CARE HEDGED TO CA (ZUH) News
'TPG Working With JPMorgan Chase Bankers To Explore Potential $5 Billion Sale Of Healthcare Payments Software Firm Lyric, Sources Said' - Reuters Exclusive
TPG is working with JPMorgan on possible Lyric sale, sources saidLyric generates about $250 million of annual EBITDA, sources saidInsurers including UnitedHealth, CVS and Humana hire Lyric to
This Illumina Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings
CVS Health Flags Elevated Medical Expenses, Sending Managed Care Lower
Ten Healthcare Stocks With A-rated Valuations and Strong Revenue Growth
Actuate Therapeutics Says Preclinical Studies Showed Synergistic Activity Of Elraglusib Combined With Revolution Medicines' Zoldonrasib And Daraxonrasib In Pancreatic Cancer Models
Actuate Therapeutics Says Preclinical Studies Showed Synergistic Activity Of Elraglusib Combined With Revolution Medicines' Zoldonrasib And Daraxonrasib In Pancreatic Cancer
Stock Index Futures Muted Day After Wall Street Closes Lower
8 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities.Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity
$100 Invested In UnitedHealth Group 20 Years Ago Would Be Worth This Much Today
UnitedHealth Group (NYSE:UNH) has outperformed the market over the past 20 years by 1.51% on an annualized basis producing an average annual return of 10.72%. Currently, UnitedHealth Group has a
Notable Healthcare Headlines for the Week: UnitedHealth, Moderna, and Medtronic in Focus
Healthcare August Recap: Moderna Jumps 156% as Biotech Shines; DaVita Sinks
Breakthrough in "Personalized Cancer Vaccines"! "Tumor Sequencing" Takes Center Stage
Breakthroughs in personalized cancer vaccines are driving up demand for tumor sequencing, making related diagnostic companies a new focus of capital markets. Positive trial results from Moderna and Merck have boosted the stock prices of firms such as Tempus AI and sparked a potential bidding war for Personalis. The market remains optimistic about the long-term growth potential of minimal residual disease (MRD) testing, although the industry still faces uncertainties related to clinical validation, commercialization, and competition.
Here's How Much You Would Have Made Owning Natera Stock In The Last 10 Years
Natera (NASDAQ:NTRA) has outperformed the market over the past 10 years by 27.54% on an annualized basis producing an average annual return of 40.97%. Currently, Natera has a market capitalization
Bloom Energy Surges on Inclusion to S&P 500; Illumina, Everpure Also Added
AstraZeneca Wins Approval of Camizestrant for Breast Cancer
$100 Invested In Revolution Medicines 5 Years Ago Would Be Worth This Much Today
Revolution Medicines (NASDAQ:RVMD) has outperformed the market over the past 5 years by 35.53% on an annualized basis producing an average annual return of 46.85%. Currently, Revolution Medicines
Alpha Buying: 4 Biotech Stocks a Healthcare Specialist Is Buying
Biotechnology investing is a strange corner of the market.A company can own a drug that may eventually produce billions of dollars in sales and still find itself scrambling to raise enough cash to
Argus Research Maintains Buy on Illumina, Raises Price Target to $235
Argus Research analyst Jasper Hellweg maintains Illumina (NASDAQ:ILMN) with a Buy and raises the price target from $180 to $235.
Tempus AI Gains as Cantor Issues New Overweight on Data and Applications Segment
30 Large-cap Stocks Flashing Strong Buy Rating
Bill Ackman Backs Mark Cuban's Drug Pricing Model: These Healthcare Stocks Could Win—Or Lose
By endorsing Mark Cuban's proposals to make prescription drug pricing more transparent, Bill Ackman shifted the conversation from healthcare policy to something investors care about just as much: